Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026 Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

What if you could bridge the gap between natural language and precise, actionable commands, all without overburdening your hardware or compromising privacy? That’s exactly what FunctionGemma promises ...

Production function estimation is a central empirical tool across many fields in economics, including industrial organization, trade, development, and applied microeconomics. Production functions ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Binance founder Changpeng Zhao said crypto platforms must prepare for the inevitable by enabling users to pass on digital assets after they die. Binance founder and former CEO Changpeng “CZ” Zhao ...

Erythritol may impair cellular functions essential to maintaining brain blood vessel health, according to researchers at the University of Colorado Boulder. Findings suggest that erythritol increases ...

The White House budget calls for slashing $17 billion in funding for the National Institutes of Health (NIH), citing the agency's failure to properly monitor risky gain-of-function research it funded ...

Section 1. Purpose. This order continues the reduction in the elements of the Federal bureaucracy that the President has determined are unnecessary. Sec. 2. Reducing the Scope of the Federal ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...